Novel therapeutic and diagnostic approaches for preeclampsia

Curr Opin Nephrol Hypertens. 2023 Mar 1;32(2):124-133. doi: 10.1097/MNH.0000000000000870. Epub 2023 Jan 9.

Abstract

Purpose of review: This review will summarize recent findings relating to the diagnostic approach to preeclampsia and current avenues of research aimed at modifying the underlying disease process.

Recent findings: Growing international consensus supports a broad preeclampsia definition that incorporates maternal end-organ and uteroplacental dysfunction. Recent evidence demonstrates that this definition better identifies women and babies at risk of adverse outcomes compared to the traditional definition of hypertension and proteinuria. Multiple studies have demonstrated the usefulness and cost-effectiveness of angiogenic biomarkers such as soluble fms-like tyrosine kinase-1 and placental growth factor as a clinical adjunct to diagnose and predict severity of preeclampsia associated outcomes. Current novel therapeutic approaches to preeclampsia target pathogenic pathways (e.g. antiangiogenesis) or downstream effects such as oxidative stress and nitric oxide. Recent findings relating to these promising candidates are discussed. Multicenter clinical trials are needed to evaluate their effectiveness and ability to improve fetal and maternal outcomes.

Summary: We provide an updated framework of the current approaches to define and diagnose preeclampsia. Disease modifying therapies (in particular, targeting the angiogenic pathway) are being developed for the first time and promise to revolutionize the way we manage preeclampsia.

Publication types

  • Review

MeSH terms

  • Biomarkers / metabolism
  • Female
  • Humans
  • Multicenter Studies as Topic
  • Placenta Growth Factor
  • Pre-Eclampsia* / diagnosis
  • Pre-Eclampsia* / therapy
  • Pregnancy
  • Vascular Endothelial Growth Factor Receptor-1 / metabolism

Substances

  • Biomarkers
  • Placenta Growth Factor
  • Vascular Endothelial Growth Factor Receptor-1